INTRODUCTION
Sleep apnea is common in congestive heart failure (CHF), affecting as many as 70% of stable CHF patients. 1, 2 Sleep apnea is also associated with a greater than 2-fold risk of CHF 3 and with increased mortality in CHF patients. 4, 5 In addition, sleep apnea may aggravate CHF risk factors such as hypertension, insulin resistance, endothelial dysfunction, and hyperlipidemia. 6, 7 Moreover, in animals and humans, experimental intermittent hypoxia simulating the respiratory instability of sleep apnea induces insulin resistance, endothelial dysfunction, and dyslipidemia. [6] [7] [8] However, the mechanisms underlying these associations are unclear.
Detrimental effects of intermittent hypoxia have largely been ascribed to end-organ hypoxic injury. Intermittent hypoxia during sleep apnea could also impair cardiometabolic function through the excessive stimulation of lipolysis, causing elevations in free fatty acids (FFA). Circulating FFA are albuminbound lipid molecules principally derived from adipose tissue lipolysis. 9 An overabundance of FFA, due to obesity or exogenous lipid infusions, can lead to insulin resistance, 10 vascular effects of Sleep Apnea on Nocturnal Free Fatty Acids in Subjects with Heart Failure jacent room. After another 2 weeks, patients with severe sleep apnea underwent a third sleep study with frequent blood sampling and the administration of supplemental oxygen at 2 liters/min. The oxygen flow could be increased up to 4 liters/min by a technician to eliminate oxygen desaturations. Hyperoxia was avoided in this protocol: subjects were monitored by continuous oximetry and supplemental oxygen was used only as needed. Some control subjects (AHI ≤ 5 on the baseline study) were found to have mild or moderate sleep apnea during the subsequent blood sampling night. Nevertheless, the AHI in control subjects remained significantly lower than in patients (Table 2 ) and demonstrated comparatively mild hypoxemia.
SLEEP APNEA AND FREE FATTY ACIDS IN SUBJECTS WITH HEART FAILURE

Assays
Samples were centrifuged to obtain plasma and stored at −80°C. Plasma FFA levels were quantified by enzymatic methods (Wako Diagnostics, Richmond, VA). All samples were run in duplicate by a technician blinded to group designations.
Statistical Analysis
Baseline variables and sleep study results were compared between groups using paired t-tests. The effect of treatment (oxygen) and group (control vs. apnea) on FFA over time were analyzed with mixed effects linear regression models. We also examined the effect of time on changes in FFA from baseline using [time × group] or [time × treatment] regressions. Additional regressions were used to correlate changes in AHI, respiratory arousals, or SpO 2 with changes in FFA in apneic subjects pre-and post-oxygen treatment. To examine effects of sleep stage, the data set was divided into wake, REM, N1, N2, and N3 stages. Two types of analysis were then performed: (1) "Instantaneous" stage analysis: FFA levels categorized according to the sleep stage of the subject at the time of FFA sampling or (2) "Stable" stage analysis: > 5 min of a single sleep stage preceding FFA sampling was required for categorization. To examine the relation between SpO 2 and FFA, the slope of the grouped ∆FFA/∆SpO 2 FFA versus SpO 2 was calculated. All statistics were performed using STATA software version 11 (College Station, TX).
RESULTS
Clinical Characteristics
Baseline characteristics of subjects are shown in Table 1 . Most CHF subjects were obese men, and several had a history of diabetes, hypertension, and hyperlipidemia. All subjects were on β-blockers and ACE-inhibitors, most were on diuretics, and many were on medical treatment for hyperlipidemia. Sleep apnea subjects had a lower ejection fraction than controls. Otherwise, controls and sleep apnea subjects did not differ significantly with
Study Protocol
Detailed methods for this study, including sleep recording and scoring, have been described by Gottlieb et al. 15 Sixty-four patients underwent screening sleep studies. Patients were admitted at 17:00 for each sleep study. A standardized meal was provided at 18:00, and subjects were fasted thereafter. On night 1 (baseline test), subjects were screened for the presence and severity of sleep apnea with a standard sleep study 22:00-06:00. Apnea was defined as a drop in the peak thermal sensor excursion by at least 90% of baseline ≥ 10 sec. Hypopnea was defined as a decrease in the nasal pressure signal excursions ≥ 10 sec accompanied by desaturation of 4% or more from preevent baseline or an arousal from sleep. From the 64 sleep studies performed, 5 patients exhibited no (AHI < 5) sleep apnea, 47 exhibited mild to moderate (AHI 5-40) sleep apnea, and 12 exhibited severe (AHI > 40) sleep apnea. The 5 patients without sleep apnea and the 12 with severe sleep apnea returned for additional sleep studies incorporating nocturnal blood sampling. Repeat sleep studies were performed 2-4 weeks after the screening sleep study. For blood sampling, a baseline sample was drawn at 22:00. The next sample was drawn at 22:40 to allow for initiation of sleep and every 20 min thereafter until 06:00. Samples were drawn without disturbing subjects through an intravenous line, extended through a port to an ad- at the start of the study. Apneic subjects showed a rapid increase in FFA that was sustained at 0.134 mmol/L (P < 0.005) higher than controls throughout the night. With oxygen, FFA in subjects with severe apnea decreased by 0.146 mmol/L (P < 0.001) throughout the night, falling to levels similar to those of controls. FFA levels changed similarly over time between apneic subjects and controls (i.e., time × apnea interaction; P = 0.13).
In subjects with severe apnea, FFA levels increased modestly as a function of time, compared to the FFA trajectory during oxygen treatment (β = 0.0002, P < 0.05). Figure 2B illustrates that oxygen decreased the mean FFA in 10 of 12 subjects. FFA decreased progressively with improvements in oxygenation (P < 0.001) whereby a rise of 1% in mean nocturnal SpO 2 was associated with a 0.034 mmol/L fall in mean nocturnal FFA ( Figure 3 ; Individual plots in Supplemental Figure S1 ). Notably, the change in FFA did not correlate significantly with the change in AHI (P = 0.36) or respiratory arousals (P = 0.124).
Effects of Sleep Stage on FFA Levels
Subjects with severe apnea exhibited increased FFA during REM, N2, and N3 sleep. These increases, which were similar in magnitude among the stages, were uniformly abolished by oxygen ( Figure 4 ). Using a more stringent sleep staging analysis requiring a stable 5-min period of unaltered sleep structure (See Methods), sleep apnea increased FFA during REM and N2 sleep, which was similarly reversed with oxygen (see Supplemental Material, Figure S2 ). Finally, we identified 33 instances of a rapid change in FFA by ≥ 0.2 mmol/L and examined if a respect to demographics, anthropometry, functional status, type of cardiomyopathy, baseline FFA level, or baseline SpO 2 .
Sleep and Breathing Patterns on Room Air and Oxygen
Sleep study results are shown in Table 2 . Compared to controls, subjects with severe apnea experienced decreased stage N3 sleep, decreased REM sleep, and a trend towards greater N1 sleep. As expected, sleep apnea subjects also had a higher AHI, respiratory arousal index, lower blood oxygen levels, and greater oxygen desaturations. They exhibited a smaller proportion of obstructive events and a trend towards a greater proportion of mixed events. Oxygen treatment did not alter sleep architecture or respiratory arousal frequency, but markedly improved most blood oxygenation indices. Oxygen lowered the AHI, while decreasing the relative frequency of mixed events and increasing the relative frequency of obstructive events.
Nocturnal FFA Profiles
Representative tracings of sleep architecture, hemoglobin oxygen saturation, and FFA from a control subject (A) and an apneic subject (B, C) are shown in Figure 1 . Increases in FFA correlated temporally with periods of oxygen desaturation. When the apneic subject (B) was placed on supplemental oxygen (C), hypoxemia corrected, and FFA levels remained relatively low throughout the night.
In Figure 2A , the plasma FFA profile of controls, apneic subjects, and apneic subjects treated with O 2 are shown at each time point during the night. All groups exhibited a similar FFA level Table S1 ).
DISCUSSION
To the best of our knowledge, this is the first study examining the effect of hypoxia on FFA during sleep. In CHF β-blockers, which might blunt nocturnal lipolysis. However, an effective inhibition of catecholamine-stimulated lipolysis would require appropriate timing and an adequate dose of medication. Most subjects in this study were taking β-1 selective blockers, which do not prevent the lipolytic stimulation of β-2 receptors on adipocytes. 19 Second, cellular hypoxia may cause a greater dependence on anaerobic glycolysis, such that FFA are not utilized for energy. 17 Third, hypoxia may impair insulin secretion 22 and adipocyte insulin sensitivity, 23 thereby interfering with the anti-lipolytic function of insulin. Remarkable surges in FFA with mild hypoxemia raise the possibility that other aspects of sleep apnea such as arousals, episodes of hypoventilation, or respiratory efforts-while insufficient to increase FFA in their own right-may interact with hypoxia in a synergistic manner to stimulate lipolysis.
Implications of Nocturnal FFA Elevations
FFA elevations are both a marker of cardiovascular mortality 22, 23 and a direct mediator of oxidative stress, inflammation, vascular dysfunction, insulin resistance, and hyperlipidemia. The magnitude of changes in FFA induced by nocturnal hypoxemia in our study could be of clinical significance. Pilz et al. followed 3315 patients after coronary angiography and found that higher FFA quartiles were associated with an increased risk of sudden cardiac death. 23 In the circulation, elevated FFA acutely suppress endothelial nitric oxide synthesis and generate reactive oxygen species, thereby impairing endothelial function 11 and increasing blood pressure. 24 In one study of diabetic subjects, FFA infusion caused a 13 mm Hg increase in systolic pressure within 4 hours, followed by a progressive decrease in vascular flow-mediated dilation, and a doubling of plasma Creactive protein over 48 hours. 25 Accumulations of FFA in the lipid pool of muscle and liver mediate several other effects. Insulin resistance occurs rapidly following elevated FFA, due to
Temporal Effects of Sleep apnea on Nocturnal FFA
By simultaneously analyzing sleep structure while collecting frequent blood samples without disturbing subjects, we were able to make several novel observations concerning the effect of sleep apnea on nocturnal lipid metabolism. FFA levels were similar between groups at baseline, but promptly diverged as patients fell asleep. Moreover, FFA levels normalized even during awakenings in the middle of the night (Figure 4 ). Arousals from sleep or sleep stage transitions per se did not influence FFA level. Rather, elevations in FFA occurred exclusively when patients were asleep and hypoxemic. These transient changes are consistent with the ~3-minute circulating half-life of FFA. 14 In light of these findings, it is not surprising that an FFA level obtained in the morning up to an hour after awakening does not correlate with apnea severity. 16 Many studies investigating metabolic consequences of sleep apnea have been similarly designed and interpreted from a chronic disease perspective. 6 These data suggest a diurnal pattern of the effect of sleep apnea on lipid metabolism. Furthermore, supplemental oxygen completely abolished a rise in FFA, despite persistent sleep fragmentation. Thus, our study dissociated effects of nocturnal hypoxemia and arousals from sleep, showing that nocturnal hypoxemia is the cause of elevated FFA in patients with apnea.
Mechanisms of Sleep Apnea-Induced Elevations of FFA
In this study, hypoxemia rather than arousals from sleep was responsible for increased FFA. Several mechanisms could account for this observation. First, hypoxia activates the sympathetic nervous system, which stimulates adipose tissue lipolysis. Acute continuous hypoxia in humans 17 or canines 18 increases plasma FFA, and the increase is prevented by propranolol or adrenal ligation, respectively. Patients in this study were taking 
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This was not an industry supported study. Dr. Smith serves as a consultant for Apnex Medical. Dr. Schwartz serves as a consultant to Apnex Medical, Sleep Science, Cardiac Concepts, and Sona Pharmaceuticals. He has received research support from ResMed unrelated to this study. Dr. Najjar has received research support from HeartWare Inc. unrelated to this study. The other authors have indicated no financial conflicts of interest. altered insulin receptor signaling in skeletal muscle. 10 Increased hepatic FFA flux accelerates the synthesis of triglycerides and their secretion in lipoproteins, 12 providing a physiologic basis for the association between sleep apnea, hepatic steatosis, and dyslipidemia. 6 Plasma FFA levels correlate with increased lipid storage and utilization by the heart, which impairs contractile function and efficiency. [26] [27] [28] Sleep apnea impacts similar parameters of oxidative stress, inflammation, vascular dysfunction, insulin resistance, and hyperlipidemia, [6] [7] [8] which may culminate in the progression of CHF. [3] [4] [5] Apolipoprotein E-deficient mice exposed to chronic intermittent hypoxia exhibit elevated FFA in association with dyslipidemia, vascular stiffness, and larger aortic atheromas. 29 Rats exposed to chronic intermittent hypoxia exhibit progressive accumulations in myocardial lipid peroxides and decreased systolic function. 30 Thus, elevations in FFA may underlie the metabolic, vascular, and cardiac dysfunction associated with sleep apnea.
Limitations
This is a relatively small study involving medically complex patients, but 643 plasma samples were analyzed from this cohort, and results were remarkably consistent. Furthermore, effects of ambient hypoxia on FFA metabolism are qualitatively similar. 17, 18, 29 These findings should be verified in otherwise healthy populations with sleep apnea, or under experimental intermittent hypoxia conditions. Second, apnea severity varied between studies, possibly reflecting changes in CHF status in the intervening weeks. It is unlikely that such variability could have accounted for the nearly ubiquitous FFA decrease brought about by oxygen treatment. Third, patients had obstructive, mixed, and central sleep apnea, as well as Cheyne-Stokes breathing, each of which might evoke different metabolic responses. Our limited sample size did not provide power to discriminate between the effects of these different forms of apnea. Fourth, our subjects experienced little N3 sleep during which growth hormone is normally secreted, stimulating lipolysis. 31 In fact, a "rebound" in N3 sleep after sleep deprivation may be accompanied by a surge in growth hormone and a rise in FFA. 32 Therefore, results of this study cannot be extrapolated to patients with greater baseline N3 sleep (e.g., in younger patients). Fifth, we studied only subjects with mild apnea (control subjects) and severe apnea; the impact of moderate apnea on plasma FFA should be further investigated. Finally, we did not show a physiologic effect of FFA in this study, so the extent to which FFA mediate cardiometabolic consequences of sleep apnea remains to be determined.
CONCLUSIONS
In CHF patients, the hypoxia of severe sleep apnea increases nocturnal FFA. Recurrent surges in nocturnal FFA may be a mechanism by which sleep apnea promotes metabolic and cardiovascular dysfunction. 
